Compare Stocks

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COV (COV)		$0.00	$65.97 ▼ $108.57	N/A	N/A	3.88 million shs	N/A
EMH Emerald Health Therapeutics	C$0.26 -3.8%	C$0.26	C$0.15 ▼ C$0.53	C$52.28M	N/A	644,760 shs	384,329 shs
IGX IntelGenx Technologies	C$0.58 +1.8%	C$0.58	C$0.17 ▼ C$0.85	C$87.32M	N/A	56,279 shs	11,848 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COV (COV)	0.00%	0.00%	0.00%	0.00%	0.00%
EMH Emerald Health Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
IGX IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%

Biggest hedge fund manager has huge warning for U.S. dollar (Ad)

Prescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."

Get the details before it's taken offline.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COV (COV)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IGX IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COV (COV)	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A
IGX IntelGenx Technologies	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COV (COV)	N/A	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	C$13.02M	4.02	C$0.33 per share	0.78	C$0.40 per share	0.64
IGX IntelGenx Technologies	C$1.75M	49.95	C$0.08 per share	7.16	C$0.05 per share	12.89

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COV (COV)	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	-C$0.70	N/A	∞	N/A	N/A	N/A	N/A	N/A
IGX IntelGenx Technologies	N/A	-C$0.08	N/A	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COV (COV)	N/A	N/A	N/A	N/A	N/A
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A
IGX IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COV (COV)	N/A	N/A	N/A
EMH Emerald Health Therapeutics	35.45	2.97	2.61
IGX IntelGenx Technologies	164.62	2.77	2.69

Ownership

Institutional Ownership

Company	Institutional Ownership
COV (COV)	N/A
EMH Emerald Health Therapeutics	N/A
IGX IntelGenx Technologies	N/A

Insider Ownership

Company	Insider Ownership
COV (COV)	N/A
EMH Emerald Health Therapeutics	N/A
IGX IntelGenx Technologies	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
COV (COV)	N/A	N/A	N/A	Not Optionable
EMH Emerald Health Therapeutics	161	205.03 million	N/A	Not Optionable
IGX IntelGenx Technologies	48	150.55 million	N/A	Not Optionable

EMH, HVO, IGX, and COV Headlines

Source	Headline
	Stocks in play: IntelGenx Corp. ca.finance.yahoo.com - April 8 at 10:41 AM
	IntelGenx Technologies Corp.: IntelGenx Updates Status of Buprenorphine Buccal Film ANDA finanznachrichten.de - April 5 at 9:46 AM
	IntelGenx Launches Preferred Share Regulation A Offering uk.finance.yahoo.com - February 20 at 12:35 PM
	NVIDIA partners with Amgen to build generative AI models for drug discovery msn.com - January 11 at 3:16 PM
	CHANGES TO BOARD OF DIRECTORS OF GEEKCO finance.yahoo.com - January 2 at 5:28 PM
	IntelGenx Technologies Corp.: IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm finanznachrichten.de - December 18 at 10:07 AM
	IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000 finance.yahoo.com - December 5 at 9:13 AM
	IntelGenx Announces Changes to its Board of Directors finance.yahoo.com - December 4 at 8:08 AM
	IntelGenx Technologies Corp.: IntelGenx Announces Shareholder Approval of Financing Transactions finanznachrichten.de - November 29 at 7:00 AM
	Closing Bell: Intelgenx Technologies Corp up on Monday (IGX) theglobeandmail.com - November 13 at 8:30 PM
	IntelGenx Technologies Corp.: IntelGenx Reports Third Quarter 2023 Financial Results finanznachrichten.de - November 10 at 7:32 AM
	Closing Bell: Intelgenx Technologies Corp up on Tuesday (IGX) theglobeandmail.com - November 7 at 10:02 PM
	IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow finance.yahoo.com - November 2 at 5:54 PM
	Closing Bell: Intelgenx Technologies Corp flat on Friday (IGX) theglobeandmail.com - October 21 at 2:23 PM
	Closing Bell: Intelgenx Technologies Corp down on Thursday (IGX) theglobeandmail.com - October 13 at 1:58 PM
	Closing Bell: Intelgenx Technologies Corp flat on Thursday (IGX) theglobeandmail.com - October 7 at 1:30 PM
	IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film finance.yahoo.com - September 19 at 8:37 AM
	IntelGenx Technologies (IGXT) Price Target Increased by 8.03% to 0.79 msn.com - August 2 at 9:33 AM
	IntelGenx Technologies Corp.: IntelGenx Announces a Change to its Board of Directors finanznachrichten.de - July 25 at 7:58 PM
	IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease finance.yahoo.com - July 25 at 8:34 AM
	IntelGenx Unveils Short-Term Commercial Objectives finance.yahoo.com - May 31 at 8:53 AM
	8-K: IntelGenx Technologies Corp. marketwatch.com - May 11 at 11:46 PM
	IntelGenx Extends Period to Exercise Certain Warrants finance.yahoo.com - April 27 at 7:54 PM
	IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film finance.yahoo.com - April 27 at 9:52 AM

Media Sentiment Over Time

Company Descriptions

(COV)

NYSE:COV

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.

Emerald Health Therapeutics

CVE:EMH

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

IntelGenx Technologies

CVE:IGX

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial